Open an account

Cypherpunk Technologies

CYPH · NASDAQ

$2.81+$0.28 (+11.07%)TodayMarket closed ·
Prev close $2.53

About CYPH

Cypherpunk Technologies, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-01-24. The firm focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.

Employees
6
Headquarters
Cambridge, Massachusetts
Listed
Jan 24, 2017
Sector
Health Care
Industry
Biotechnology
Website
leaptx.com

CYPH key statistics

Market cap
302.82M
Price-earnings ratio
4.52
Dividend yield
—
Average volume
14.52M
Volume
12.71M
Open price
$2.48
High today
$2.89
Low today
$2.42
52 Week high
$4.19
52 Week low
$0.393

Cypherpunk Technologies (CYPH) at a glance

As of Oct 20, 2026, Cypherpunk Technologies (CYPH) shares are priced at $2.81, giving the company a market cap of 302.82M and a price-to-earnings ratio of 4.52.

Today the stock has traded between $2.42 and $2.89. The current price is 16.1% above the day's low and 2.8% below its high.

Volume so far is 12.71M shares, in line with the average of 14.52M shares a day.

Over the past year Cypherpunk Technologies has ranged from $0.393 to $4.19, and now sits 64% of the way up that range.

Cypherpunk Technologies met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.18 per share against an estimate of -$0.0306.

The average analyst price target is $5.00, 77.9% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $5.00
Low
$4.95
Now
$2.81
High
$5.14

CYPH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 157.0% on average.

  1. Q1 FY24: reported -$0.51 per share against an estimate of -$0.5967
  2. Q2 FY24: reported -$0.52 per share against an estimate of -$0.4386
  3. Q3 FY24: reported -$0.44 per share against an estimate of -$0.4896
  4. Q4 FY24: reported -$0.37 per share against an estimate of -$0.3672
  5. Q1 FY25: reported -$0.37 per share against an estimate of -$0.3876
  6. Q2 FY25: reported -$0.40 per share against an estimate of -$0.2958
  7. Q3 FY25: reported -$0.08 per share against an estimate of -$0.2448
  8. Q2 FY26: reported $0.18 per share against an estimate of -$0.0306

CYPH news

  • Avi Kapoor

    First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday

  • Avi Kapoor

    Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

  • Avi Kapoor

    Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday

  • 10 Health Care Stocks Whale Activity In Today’s Session

  • Press releasePRNewswire

    Cypherpunk Technologies Appoints Amanda Fabiano to Board of Directors

  • 8 Health Care Stocks Whale Activity In Today’s Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

Similar companies

Companies in the same industry as Cypherpunk Technologies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.